Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.

•Stage III lung cancer requires multidisciplinary collaboration between medical oncology, surgery, and radiation oncology.•Molecular testing is necessary to determine if a patient will be eligible for adjuvant therapy and emerging neoadjuvant strategies.•Neoadjuvant osimertinib is being explored as an induction strategy in patients with stage IIIA EGFR-mutant non–small-cell lung cancer. Further work is required to define which patient population will best benefit from this therapeutic approach.